Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: seekingalpha
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.620
Low
8.00
Averages
18.43
High
40.00
Current: 13.620
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
COMP360 Shows Breakthrough Progress in Treatment-Resistant Depression
- Clinical Trial Results: COMP360 demonstrated that 39% of participants in the COMP006 Phase 3 trial achieved a clinically meaningful reduction in depressive symptoms by week six, with effects maintained for at least 26 weeks, indicating its potential value in treating treatment-resistant depression.
- Safety Profile: COMP360 exhibited a generally well-tolerated and safe profile in a highly chronic depression population, with the majority of treatment-emergent adverse events being transient and occurring predominantly on the day of dosing, underscoring its safety and tolerability.
- NDA Progress: The rolling New Drug Application (NDA) for COMP360 is underway, with final submission expected to be completed in Q4 2026, and a commercial launch anticipated in the first half of 2027, marking a significant milestone for the company in the mental health space.
- Market Potential: The successful development of COMP360 could provide new treatment options for millions of patients with treatment-resistant depression, potentially transforming the standard of mental health care, reducing patient suffering, and improving quality of life.
See More
Compass Pathways Grants Equity Awards to New Employees
- Equity Award Program: Compass Pathways plc granted equity awards on July 1, 2026, to eight newly hired non-executive employees, totaling 63,685 stock options and 30,300 restricted share units, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the mental health sector.
- Option Exercise Price: The granted options have an exercise price of $13.29 per share, matching the closing price of the company's American Depositary Shares on the grant date, which aligns employee interests with company performance and promotes long-term value creation.
- Vesting Schedule: These options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, a structure that not only incentivizes long-term employee retention but also enhances team stability and execution capability.
- Regulatory Compliance: In accordance with NASDAQ Listing Rule 5635(c)(4), the equity awards were approved by the Compensation and Leadership Development Committee of the Board, ensuring the company's compliance and transparency in talent attraction efforts.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Kailera Appoints New Chief Corporate Affairs Officer
- Executive Appointment: Kailera Therapeutics has appointed Kathleen Tregoning as Chief Corporate Affairs Officer to advance its obesity clinical trials and navigate the rapidly evolving treatment landscape, thereby enhancing the company's leadership position in obesity care.
- Extensive Experience: Tregoning brings over 20 years of global corporate affairs experience, having held executive roles in biopharmaceutical companies, particularly her successful tenures at Cerevel Therapeutics and Sanofi, which will provide Kailera with strategic insights to navigate complex policy and regulatory environments.
- Pipeline Development: Kailera is focused on developing multiple GLP-1-based therapeutic options and is advancing four clinical-stage candidates, including the global Phase 3 trial of KAI-9531, which is expected to offer significant weight loss benefits for obesity patients.
- Market Outlook: As obesity becomes an increasingly pressing issue, Kailera's innovative product portfolio aims to meet the needs of patients and healthcare systems, and Tregoning's addition is expected to enhance the company's competitiveness in this dynamic market, driving its long-term growth strategy.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
COMP360 Shows Breakthrough Progress in Treatment-Resistant Depression
- Clinical Trial Results: COMP360 demonstrated that 39% of participants in the COMP006 Phase 3 trial achieved a clinically meaningful reduction in depressive symptoms by week six, with effects maintained for at least 26 weeks, indicating its potential value in treating treatment-resistant depression.
- Safety Profile: COMP360 exhibited a generally well-tolerated and safe profile in a highly chronic depression population, with the majority of treatment-emergent adverse events being transient and occurring predominantly on the day of dosing, underscoring its safety and tolerability.
- NDA Progress: The rolling New Drug Application (NDA) for COMP360 is underway, with final submission expected to be completed in Q4 2026, and a commercial launch anticipated in the first half of 2027, marking a significant milestone for the company in the mental health space.
- Market Potential: The successful development of COMP360 could provide new treatment options for millions of patients with treatment-resistant depression, potentially transforming the standard of mental health care, reducing patient suffering, and improving quality of life.
See More
Compass Pathways Grants Equity Awards to New Employees
- Equity Award Program: Compass Pathways plc granted equity awards on July 1, 2026, to eight newly hired non-executive employees, totaling 63,685 stock options and 30,300 restricted share units, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the mental health sector.
- Option Exercise Price: The granted options have an exercise price of $13.29 per share, matching the closing price of the company's American Depositary Shares on the grant date, which aligns employee interests with company performance and promotes long-term value creation.
- Vesting Schedule: These options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, a structure that not only incentivizes long-term employee retention but also enhances team stability and execution capability.
- Regulatory Compliance: In accordance with NASDAQ Listing Rule 5635(c)(4), the equity awards were approved by the Compensation and Leadership Development Committee of the Board, ensuring the company's compliance and transparency in talent attraction efforts.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Kailera Appoints New Chief Corporate Affairs Officer
- Executive Appointment: Kailera Therapeutics has appointed Kathleen Tregoning as Chief Corporate Affairs Officer to advance its obesity clinical trials and navigate the rapidly evolving treatment landscape, thereby enhancing the company's leadership position in obesity care.
- Extensive Experience: Tregoning brings over 20 years of global corporate affairs experience, having held executive roles in biopharmaceutical companies, particularly her successful tenures at Cerevel Therapeutics and Sanofi, which will provide Kailera with strategic insights to navigate complex policy and regulatory environments.
- Pipeline Development: Kailera is focused on developing multiple GLP-1-based therapeutic options and is advancing four clinical-stage candidates, including the global Phase 3 trial of KAI-9531, which is expected to offer significant weight loss benefits for obesity patients.
- Market Outlook: As obesity becomes an increasingly pressing issue, Kailera's innovative product portfolio aims to meet the needs of patients and healthcare systems, and Tregoning's addition is expected to enhance the company's competitiveness in this dynamic market, driving its long-term growth strategy.
See More
Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%
- Enrollment Milestone: Helus Pharma's HLP003 Phase 3 trial has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026, indicating the company's potential in the mental health treatment space.
- Clinical Trial Significance: Eric So noted that the continued enrollment progress underscores the execution of the clinical program, bringing them closer to the anticipated topline data release, which could provide a transformative treatment option for patients with major depressive disorder, enhancing the company's position in a competitive market.
- FDA Breakthrough Designation: HLP003 has received FDA Breakthrough Therapy Designation, aimed at expediting development and review, signaling significant improvement potential in treating major depressive disorder, thus boosting investor confidence in the program.
- Strong Market Demand: Major depressive disorder affects hundreds of millions globally, with traditional treatments offering limited relief; if HLP003 can validate its efficacy in Phase 3 trials, it could reshape the management of depression.
See More
